Title Page
ABSTRACT
국문 초록
PREFACE
Contents
NOMENCLATURE 19
CHAPTER 1. INTRODUCTION 20
CHAPTER 2. MATERIALS AND METHODS 23
2.1. Development of a novel MD mouse model 23
2.1.1. Animals 23
2.1.2. BCAS operation, post-surgical monitoring, and euthanasia methods 24
2.1.3. Neurobehavioral tests 24
2.1.4. Tissue preparation and immunohistochemistry (IHC) 26
2.1.5. Quantification and statistics 26
2.2. Verifying the efficacy of secretome from stem cells (MFG-E8) in MD mouse 27
2.2.1. Animals 27
2.2.2. Secretome from induced pluripotent stem cell (iPSC): MFG-E8 27
2.2.3. Neurobehavioral tests 28
2.2.4. Tissue preparation and IHC 28
2.2.5. Quantification and statistics 28
CHAPTER 3. RESULTS 29
3.1. Development of a novel MD mouse model 29
3.1.1. Neurobehavioral functions of MD mouse [Figure 3] 29
3.1.2. IHC for MD mice [Figure 4] 29
3.2. Efficacy of MFG-E8 in MD mice 30
3.2.1. Efficacy in neurobehavioral functional outcome [Figure 5] 30
3.2.2. Efficacy in immunohistology findings [Figures 6, 7] 30
CHAPTER 4. DISCUSSION 32
CHAPTER 5. CONCLUSION 36
REFERENCES (OR BIBLIOGRAPHY) 37
Table 1. Steps for passive avoidance test 25
Figure 1. Flowchart of the experiments A. Experiment to develop a novel mixed dementia animal model... 40
Figure 2. Cross sectional images of MOAB-2 immunoreactivity with region of interest (ROI) settings in AD (A) and VaD (B) mice, respectively... 41
Figure 3. Results of neurobehavioral tests for the development of a novel MD animal model... 42
Figure 4. Results of IHC for the development of a novel MD animal model A. Representative images of MOAB-2 immunoreactivity counterstained... 43
Figure 5. Results of neurobehavioral tests to verify the efficacy of MFG-E8 in MD animal model... 44
Figure 6. Results of IHC to verify the efficacy of MFG-E8 in MD animal model A. Representative images of 6E10 immunoreactivity counterstained with... 45
Figure 7. Results of IHC to identify the mechanism of MFG-E8 in MD animal model... 46